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Abstract
Background: Official descriptive data from France showed a strong increase in breast-cancer incidence between
1980 to 2005 without a corresponding change in breast-cancer mortality. This study quantifies the part of
incidence increase due to secular changes in risk factor exposure and in overdiagnosis due to organised or
opportunistic screening. Overdiagnosis was defined as non progressive tumours diagnosed as cancer at histology
or progressive cancer that would remain asymptomatic until time of death for another cause.
Methods: Comparison between age-matched cohorts from 1980 to 2005. All women residing in France and born
1911-1915, 1926-1930 and 1941-1945 are included. Sources are official data sets and published French reports on
screening by mammography, age and time specific breast-cancer incidence and mortality, hormone replacement
therapy, alcohol and obesity. Outcome measures include breast-cancer incidence differences adjusted for changes
in risk factor distributions between pairs of age-matched cohorts who had experienced different levels of screening
intensity.
Results: There was an 8-fold increase in the number of mammography machines operating in France between
1980 and 2000. Opportunistic and organised screening increased over time. In comparison to age-matched cohorts
born 15 years earlier, recent cohorts had adjusted incidence proportion over 11 years that were 76% higher [95%
confidence limits (CL) 67%, 85%] for women aged 50 to 64 years and 23% higher [95% CL 15%, 31%] for women
aged 65 to 79 years. Given that mortality did not change correspondingly, this increase in adjusted 11 year
incidence proportion was considered as an estimate of overdiagnosis.
Conclusions: Breast cancer may be overdiagnosed because screening increases diagnosis of slowly progressing
non-life threatening cancer and increases misdiagnosis among women without progressive cancer. We suggest
that these effects could largely explain the reported “epidemic” of breast cancer in France. Better predictive
classification of tumours is needed in order to avoid unnecessary cancer diagnoses and subsequent procedures.
Background
Between 1980 and 2005, age-standardized cancer inci-
dence in France increased by 38%, primarily due to
increased reported prostate cancer incidence in men
and breast and lung cancer among women [1]. The
case-fatality rate of breast cancer estimated from inci-
dence and mortality decreased from 39% in 1980 to 23%
in 2005. The increase in breast cancer incidence may be
related to increasing exposure to causal factors, such as
use of hormone replacement therapy (HRT), alcohol,
obesity and change in family size, but may also be an
artefact of increased screening.
Reports from the International Agency for Research
on Cancer (IARC) and from the French National Insti-
tute for Health Research (INSERM) considered the dis-
tinction between real and artificial increases in cancer
frequency in France by emphasizing mortality data over
i n c i d e n c ed a t a[ 2 , 3 ] .W h e nc o m p a r i n gt h et r e n d s
between cancer sites, the IARC report hypothesised that
the net impact of early detection methods is to increase
reported cancer incidence independently of environmen-
tal or lifestyle risk factors. Figure 1 shows breast cancer
* Correspondence: Junod.bernard@wanadoo.fr
1FORMINDEP, Roubaix, France. Previous position: Department of
Epidemiology, Ecole des Hautes Etudes en Sante Publique Rennes, France
Full list of author information is available at the end of the article
Junod et al. BMC Cancer 2011, 11:401
http://www.biomedcentral.com/1471-2407/11/401
© 2011 Junod et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.incidence and breast cancer mortality for the period
1980 to 2005, revealing a substantial discrepancy. If the
true incidence in breast cancer was not increasing over
time, both screening and improvements in treatment
should have substantially reduced breast-cancer
mortality.
The goal of breast-cancer screening (testing for the
disease in asymptomatic patients) is to reduce mortality
by diagnosing and treating tumours earlier in the disease
process. Initially, screening programs will increase rates
of cancer diagnosis because prevalent tumours are
detected earlier. After the introduction of screening,
when the reservoir of undiagnosed cases is depleted, a
decline of incidence is expected before a new steady
state is achieved [4]. However, recent papers suggest
that publicly available mammography screening pro-
grams are associated with 10% to 50% overdiagnosis
[5,6], where overdiagnosis is defined as the detection,
through screening, of disease that would never have
been diagnosed in the absence of screening and thus
unlikely to have imposed health consequences through-
out life [7]. Increase in screening activity also occurs
without organized screening program. For example,
after careful modelling, overdiagnosis was over 40% for
the younger cohorts that had been exposed to mammo-
grams in Catalonia [8].
A Norwegian study suggested that mammography
screening leads to a larger increase in detected invasive
breast cancer than can be explained by earlier diagnosis
or increased exposure to risk factors. The authors sug-
gested that mammography screening detects many
tumours that otherwise would spontaneously regress [9].
Most breast cancers are diagnosed by biopsy following
identification by self palpation, clinical examination by a
physician, or by mammography. Overdiagnosis is
inevitable when testing for asymptomatic disease in
almost all screening programs. Clinicians use histology
for diagnosing a true progressive disease that would
metastasise and cause death without treatment if no
other health problem interfered with its progression.
The validity of testing for true progressive cancer by his-
tology depends on the sensitivity and the specificity of
slides from the biopsy. The number of diagnosed cancer
c a s e si na ne x a m i n e dp o p u l a t i o ni st h es u mo fw o m e n
with progressive cancer correctly diagnosed and of
women diagnosed with a cancer that would not progress
to clinical detection in their lifetime. The number of
true progressive cancers detected in a population reflects
the frequency of examinations among women with pro-
gressive cancer, the sensitivity of diagnosis procedures
before the biopsy, and the sensitivity of examination by
histology.
Global sensitivity is the proportion of progressive can-
cers correctly identified in a population. All nonprogres-
sive tumours diagnosed as cancer by histology are
overdiagnoses. They reflect the frequency of examina-
tions among women without a progressive cancer, the
specificity of diagnostic procedures before the biopsy,
and the proportion of women without a progressive can-
cer correctly identified when examined by histology. All
the cancer-free women not tested contribute to increase
global specificity: the proportion of women without a
true progressive cancer correctly considered as cancer
free in the population. Screening increases global sensi-
tivity. But by doing this, it also results in decreasing glo-
bal specificity, which in turn produces more
overdiagnosis.
Overdiagnosis includes all nonprogressive tumours
diagnosed as cancer using histology and those progres-
sive cancers that would never cause symptoms or death
during a patient’s lifetime. Such cases are functional
overdiagnoses related to a patient’s outcome rather than
to the physiological or structural causes of overdiagno-
sis. Functional overdiagnosis depends not only on the
cancer but also on competing causes of death and life
expectancy. It occurs more frequently when screening is
performed among women with a short remaining life
expectancy and when global sensitivity is high.
Our study investigates how the increase in mammo-
graphy screening is associated with increase in the
apparent breast-cancer incidence in France. Such infor-
mation is relevant to the debate about the benefits and
side effects of breast-cancer screening [10-15].
Methods
This investigation is restricted to 1980 - 2005 and to
French districts of metropolitan France, the European
part of the country. Districts of metropolitan France is
Annual rate 
for 100000
1980      1985       1990      1995      2000       2005
Breast cancer mortality rates
Breast cancer incidence rates
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100
150
200
250
300
Year
60.4 64.9 66.8 66.6
60.8 63.2
269.1
242.9
215.7
193.1
171.1
153.6
Figure 1 Age standardised breast-cancer deaths and breast-
cancer incidence by calendar year in France. Standard: age
structure of women aged 35 and more in 1992.
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métropolitaine”.
Data
Breast cancer deaths and the populations of women
were provided by the Center for Epidemiology of Medi-
cal Causes of Death (CepiDC) [16]. The annual number
of newly diagnosed invasive breast cancer, and the
population of women in France were used to estimate
the time trend of breast-cancer frequency. Diagnoses of
invasive breast cancer were estimated from population-
based cancer registries operating in France [17]. For
year 1992 (the middle of the study period) the national
estimate was based on 2193 reported cases [18]. Inci-
dence of invasive cancer was provided up to 2005 by the
French Institute for Public Health Surveillance [19].
A g ea n dt i m es p e c i f i ce x p o s u r et oH R T[ 2 0 , 2 1 ] ,a l c o -
hol [22], and obesity [23] in France were estimated from
published data. For HRT, age specific prevalence was
based on two cohorts available in France: “ESPS-EPAS”
(sample from the social security registry) and “3C”
(women from Bordeaux, Dijon and Montpellier). The
relative risk estimates were obtained from four models
used in the report [20]. Each model takes into account
three types of HRT use: oestrogen only, oestrogen plus
progesterone, and oestrogen plus progestin. Women
were considered exposed to alcohol if they drank at
least 6 glasses or more on one occasion and/or at least
14 glasses a week. Obesity was defined by a body mass
index equal to or larger than 30 kg/m
2. For alcohol and
obesity, relative risk estimates were based on interna-
tional literature [24].
Changes in diagnostic procedure
We used two data sources to evaluate changes in mam-
mography practice. First, we estimated the number of
mammography machines registered annually in France,
using the same methods from the 1970s to 2000 [25].
The mean number of screening tests performed per
mammography machine is available for 1988 [26]. Sec-
ond, we estimated the implementation of organised
breast-cancer screening programs by mammography in
France up to 2004 [27]. For two districts we also had
the age distribution of women undergoing mammogra-
phy when tested either by an organised program or by
private initiative in 1995 [28].
Change in incidence due to change in risk factor
exposure
Breast-cancer incidence attributable to change in expo-
sure to risk factors over time is obtained in age-specific
categories. It is computed from incidence in the refer-
ence period, available exposure prevalence for each
period, and from relative risk estimates. Additional file 1
provides formulas used for these calculations.
Overdiagnosis estimate from change in incidence and
breast-cancer mortality
Change in incidence proportion was obtained by com-
paring age-matched cohorts 15 years apart. Comparisons
of incidence within a pair of cohorts submitted to differ-
ent screening activity were performed separately for
middle age women aged 50 to 64 and for elderly women
aged 65 to 79. In each pair, the reference cohort was
observed at an earlier calendar period when screening
activity was less intense. The reference cohort was
observed 15 years before the comparison cohort for
both age groups of women. For middle-aged women,
the reference cohort included women born between
1926 and 1930 and was compared to the cohort of
women born in 1941-1945. For elderly women, the
reference cohort included women born in 1911-1915
and was compared to the 1926-1930 birth cohort. For
both middle age and elderly women, incidence was
observed yearly for 5-years age groups. Change in crude
incidence proportion associated with a 15 year change
in screening activity is the difference between 11 years
incidence proportion within each pair of cohorts. The
detailed computation of incidence proportion is given in
additional file 2. The same procedure was used for
breast-cancer mortality.
Within each pair of cohorts, incidence attributable to
change in risk factor prevalence and to change in mor-
tality proportion, if any, was subtracted from crude inci-
dence proportion to get an estimate of overdiagnosis
between the two cohorts in the comparison.
Statistical Methods
Confidence limits (CL) were obtained from a normal
approximation to the distribution of proportions for the
comparison of initial procedure leading to breast-cancer
diagnosis over time. Confidence limits for differences
between incidence proportions were obtained using
French official data and observed cases in French cancer
registries operating in 1992 [18]. Confidence limits were
not calculated for estimates of the full population. See
additional file 2 for formulas.
Results
Time trend for availability and use of mammography
screening
The number of mammography machines increased stea-
dily from 308 in 1980, 499 in 1984, 1351 in 1990, 2282
in 1994 to 2511 in 2000. There were about 8 times
more mammography machines available in 2000 than in
1980.
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program in 1989, 13 in 1994 and 31 in 1999. In 2004,
all 96 districts had an organised screening program.
Screening began at age 50, and in 1999, the upper age
limit for inviting women to be screened every second
year was extended from 69 up to 74 years of age. Dur-
ing the whole period, screening practices were not
restricted to the women included in organised programs.
In two districts with an organised program in 1995,
the mammography rate before 50 or after 69 years of
age was 59% of the mammography rate in the organized
screening program for women aged 50 to 69 [28]. In
1988, the mean number of screening mammography per
mammography machine amounted to 1050 per year
[26,28].
Time trend of exposure to risk factor
Changes in exposure to risk factors are summarised in
Table 1. In comparison to 1980-1990, there was an
increased prevalence of HRT use and obesity by 1995-
2005, whereas alcohol consumption in women
decreased.
Changes over time in breast-cancer incidence and breast-
cancer mortality
Figure 2 shows the age-specific increase of breast-cancer
incidence over time. The largest increase occurred for
women 45 to 74 years of age. For women aged 50 to 69,
the incidence in 2005 is twice the incidence in 1980.
The largest increase occurred in 2005 for the 60 to 64
age group. In 2005, the breast-cancer incidence
decreased after age 74 compared to rates for women
aged 60-69; the shape of the age-specific incidence rate
changed from being non-declining with age to being
bell shaped.
In cohorts that had more intensive breast screening,
we might expect a reduction of breast-cancer incidence
after age 74 since slow growing tumours should have
been detected but this was not seen. Within each pair of
cohorts, the observed increase in incidence is even lar-
ger at the end of the period of comparison than 11
years before. This is visible in Figure 3 for age groups
65-69 to 75-79. Age-specific breast-cancer mortality was
similar in the two pairs of cohorts. In the pair of cohorts
of middle age women (50 to 64), the cumulative breast-
cancer mortality rates were 6.7/1000 from 1980 to 1990
and 6.6/1000 from 1995 to 2005. In the cohorts of
elderly women (65-79), the cumulative breast-cancer
mortality rates were 9.9/1000 from 1980 to 1990 and
10.7/1000 from 1995 to 2005.
Estimates of overdiagnosis
Incidence rates observed in the cohorts are given in Fig-
ure 3. For women aged 50 to 64, the 11-years incidence
proportion was 20/1000 in the reference cohort
observed from 1980 to 1990. It increased 80% [95% CL:
72%, 89%] to 37/1000 in the age-matched cohort
observed from 1995 to 2005. For women aged 65 to 79,
the 11-year incidence proportion was 24/1000 in the
reference cohort observed from 1980 to 1990. It
increased 27% [95%CL 20%, 34%] to 31/1000 in the age-
matched cohort observed from 1995 to 2005.
Overdiagnosis estimates take into account changes in
incidence proportions, and adjustments due to change
in risk factors prevalence, as given in Table 2. Given
that breast-cancer mortality changed less than 0.1/1000
Table 1 Change over time in the prevalence of risk factor exposure
Age group HRT (RR = 1.17 [21]
a) Alcohol (RR = 1.7 [24]
b) Obesity (RR = 2.0 [24]
c)
1980-1990 1995-2005 1980-1990 1995-2005 1980-1990 1995 -2005
50-59 7.9% 31.6% 16.7% 13.5% 4.1% 6.4%
60-69 7.7% 30.7% 7.0% 5.7% 6.1% 10.4%
70-79 2.3% 9.0% 3.7% 3.0% 6.1% 10.4%
a RR resulting from the four available models in table six of “AFSSAPS report”[21]. RR = Total of expected exposed cases (3922.15)/Total of expected non-exposed
cases (3358.78) = 1.17
Prevalence data restricted to population based samples: “ESPS-EPAS” and “3C” [21].
b Interpolation between delivered results (1.5 and 2.0)
c Prevalence in age group 60-69 was extrapolated to age group 70-79
Age group
100
150
200
250
Annual rate
per 100000
50
300
350
400
1980
1992
0
6
0
-
6
4
5
5
-
5
9
6
5
-
6
9
7
0
-
7
4
7
5
-
7
9
4
5
-
4
9
5
0
-
5
4
4
0
-
4
4
1980: lower screening  1992: intermediate screening  2005: higher screening
2005 112 %
Figure 2 Breast-cancer incidence rates by age and according
to screening activity. France, 1980, 1992 and 2005.
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age group, it was not taken into account for adjust-
ments. Overdiagnosis estimates are slightly lower than
the crude difference between incidence proportions
within each pair of cohorts. Adjustment for increase in
HRT use and in obesity resulted in a slight reduction in
the crude difference between incidence proportions. On
the contrary, decrease in alcohol consumption contribu-
ted to a small increase in the overdiagnosis estimate for
each considered pair. Overdiagnosis estimates from
1995 to 2005 were 76% (95% CL: 67%; 85%) for women
aged 50 to 64 and 23% [95% CL: 15%; 31%] for women
aged 65 to 79.
Discussion
We observed that standardised breast-cancer incidence
rates increased steadily from 1980 to 2005 as use of
screening tools increased, whereas age standardised
breast-cancer mortality rates changed only slightly dur-
ing this period. These trends might reflect a progressive
increase in unknown breast cancer exposure and a
decrease in case fatality due to better treatment. How-
ever, our results are consistent with other studies that
fail to demonstrate a benefit of screening for breast can-
cer at the population level.
Opinion on the value of screening mammography
remains divided. Many investigators, particularly from
the radiology community, support population screen-
ing [10,12,29]. On the other hand, some but not all
meta-analysis of randomisedc o n t r o l l e dt r i a l sf a i lt o
document survival benefits [14]. Meta analyses may
come to different conclusions because they apply dif-
ferent study exclusion criteria. Those with stricter
quality criteria tend to favour the null effects of
screening, particularly for women younger than 50
years. However, some have argued that the choice in
quality criteria is subjective [12] or due to assumptions
[11]. Further, systematic quasi-experimental evalua-
tions in Norway reported poor survival benefit in those
screened [30]. Similar studies from Denmark suggest
that the decline in breast cancer mortality was greater
in regions without screening than it was in areas
where screening was phased in earlier [31]. A recent
study used WHO data to compare trends in breast
cancer mortality in three pairs of European countries:
Northern Ireland v. Republic of Ireland, Netherlands v.
Belgium, and Sweden v. Norway. Although one mem-
ber of each county pair had a more aggressive screen-
ing policy, reductions in breast cancer mortality were
similar for in all three pairs. These findings are consis-
tent with clinical trials and other quasi-experiments
that have failed to show significant reductions in mor-
tality directly attributable to mammography [32].
Well-conducted screening programs should lead to an
initial increase of both prevalent cases and lead time,
and then to a subsequent decline of observed advanced
tumours which was not observed. After 74 years of age,
when women are not invited by organised screening
programs, the incidence rate should not increase as
Age group
100
150
200
250
Annual rate
per 100000
6
0
-
6
4
5
5
-
5
9
7
0
-
7
4
6
5
-
6
9
7
5
-
7
9
1990
2000
2005
50
300
350
400
1995
2005
1980
1985
1980
80 %
1990
Birth cohort 1911-1915
Birth cohort 1926-1930
Birth cohort 1941-1945
27 %
0
2000
1985
5
0
-
5
4
1980 to      1990: lower screening;          1995 to     2005: higher screening 
1995
Figure 3 Breast-cancer incidence in birth cohorts subject to
different levels of screening activity. Crude incidence proportion
increase in %. France, 1980 to 2005.
Table 2 Breast-cancer incidence proportion from 1980-1990 to 1995-2005 in France
Age in the
cohort
Incidence proportion
of breast cancer
diagnosis for 11 year
periods
Incidence proportion
attributable to
change in risk factor
exposure from 1980-
1990 to 1995-2005
Relative change in adjusted incidence proportion attributable to
overdiagnosis
Cases per 1000 Cases per 1000 Adjusted relative increase
(1) (2) (3) (4) (5) {(2)-(1)-(3)-(4)-(5)}/(1)
1980 -
1990
1995 -
2005
HRT Alcohol Obesity
50-64 20.4 36.8 .82 - .40 .48 76.0%
95% CL:66.7; 85.0
65-79 24.3 30.9 .89 - .25 .33 23.0 %
95% CL: 15.2%; 30.9%
Comparison of 11 year follow-up of age matched cohorts 15 years apart
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cohort [33]. Nonetheless, compared to earlier ages, the
increase in breast-cancer incidence was even larger for
women aged 75-79 in 1995 than in 1990, when screen-
ing was less intense up to 74 years of age. The unex-
pected increase in cancer incidence in older women
may reflect overdiagnosis due to greater screening
[34,35].
The period of observation was chosen to ensure stabi-
lity in the recording systems for both death, incidence
and in the nomenclatures used. Before 1978, breast-can-
cer incidence was not available and breast-cancer mor-
tality trend was biased by the fact that death due to
breast cancer was also declared as “cancer” without spe-
cifying the site of the primary tumour. Statistics are
available on the age frequency distribution of surgical
interventions performed in 1999 for breast cancer in
France [36]. Among women aged 50 to 79, there are
16.5% more interventions than incident cases of invasive
c a n c e r .T h i sd i f f e r e n c ei sc onsistent with inclusion of
women operated more than once or for ductal carci-
noma in situ.
Our study has several important limitations. Only a
small proportion of the French population is included in
cancer registries (about 7% in the middle of the study
period). In addition, we can not rule out secular changes
in other breast-cancer risk factors like age at first birth,
nulliparity or socioeconomic status. Adjustments for
changes in HRT, alcohol and obesity prevalence over
time are by nature imperfect.
Organised screening programs do not give an
unbiased appraisal of actual screening activity in France:
they do not include opportunistic screening, which is
substantial [28]. An increase over time in the number of
m a m m o g r a p h ym a c h i n e si nF r a n c ei sl i k e l yt oe x p l a i n
changes of initial procedures leading to breast-cancer
diagnosis, as shown in a study conducted in the district
of Haute Vienne [37]. During 1986-1989, 80% of the
cancers (298 of 372) were discovered by the patient,
while this proportion fell to 52% (176 of 341) during
1997-1998. The difference between the two groups is
28.5% [95% CL 21.8%, 35.2%]. This reduction was pri-
marily offset by the increase in the proportion of breast
cancer discovered by mammography: 24.5% [95% CL
20.2%; 28.8%]. The shorter duration of the second per-
iod indicates increased frequency of breast-cancer diag-
nosis. This increase observed 10 years apart in the
district of Haute Vienne is about 2/3 of the correspond-
ing increase observed 15 years apart in cohorts from 50
to 79 years of age at the national level.
A1 %d r o po fg l o b a ls p e c i f i c i t yw o u l de x p l a i nt h e
observed increase in breast-cancer incidence in France.
Suppose that among 1000 women, 4 have undetected
true invasive breast cancer and 996 do not have invasive
breast cancer. If the women are not examined, the four
cases will eventually be diagnosed if they become symp-
tomatic and the specificity is 100%. If these 1000
women undergo diagnostic procedures with a global
sensitivity of 90% and a global specificity of 99%, we
would get 90% of 4, that is 3.6 true positives; 99% of
996, that is about 986 true negatives; 10% of 4, or 0.4
false negative and 1% of 996, that is about 10 false posi-
tive. The positive predictive value among the 13.6 diag-
nosed “cancer” is thus about 3.6/13.6, less than 30%.
This example illustrates how overdiagnosis may increase
with screening even without changes in the intrinsic
sensitivity and specificity of each diagnostic procedure.
Changes in the studied risk factors did not explain
much of the increase in breast-cancer incidence over
time. The emergence of overdiagnosis as a possible
explanation of the incidence trend is related to the long
period over which screening intensity has been
increasing.
An analogous divergence between the trends in inci-
dence and mortality was observed from 1927 through
1947 in Canada. Confidence in the efficacy of Halsted’s
radical procedure contributed to increasing early screen-
ing by breast self-examination. McKinnon hypothesised
that the limitations of diagnosis confirmed by histology,
which is “fraught with uncertainty”, explained all or part
of the apparent improvement in survival of cancers
screened at an early stage during this period [38].
Undetected invasive breast cancers exist among
women at the time of death due to other causes. Welch
and Black used autopsy studies to estimate the size of
the “reservoirs” of ductal cancer in situ [39]. These stu-
dies also revealed undetected invasive breast cancer
among women who died from other causes [40-43].
Other publications reporta ne l e v a t e df r e q u e n c yo f
slowly or non-progressing lesions [44], some likely to be
misdiagnosed as invasive cancer [45]. It is therefore pos-
sible that opportunistic screening explains most of the
excess of overdiagnosis before age 50 and after age 74.
Similar breast-cancer mortality in the cohort observed
from 1980 to 1990 and the cohort observed from 1995
to 2005 also indicates overdiagnosis as a possible expla-
nation for the incidence increase from age 40 to 79.
T h e2 0 0 3r e p o r to ft h eF r e n c hC a n c e rC o m m i s s i o n
furnishes a key to interpreting this increased incidence:
“Overdiagnosis (diagnosis of tumours at the borderline
of malignancy) constitutes a serious problem because it
can artificially increase the incidence of cancer and the
result of treatment” [46]. In 2005, a discussion at the
French Academy of Medicine suggested that the defini-
tion of cancer should change to include evidence of the
progression of the tumour over time [47].
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In summary, there has been a substantial increase in
breast-cancer incidence in France without a correspond-
ing increase in mortality. Although this could be
explained by a perfect balance between an increased
incidence and improved survival, we think the increased
breast-cancer incidence observed in France since 1980
largely reflects an increase in overdiagnosis. The latter
includes misdiagnoses and true cancer lesions that
would not have had any impact on the health of the
women during their normal lifetime. Better predictive
classification of tumours is needed in order to avoid
unnecessary cancer diagnoses and subsequent
procedures.
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